Evidence map›Paper›PMID 40176316›Full record

ArticleACS nano2025

Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.

Gangyin Zhao, Ye Zeng, Wanli Cheng, Sofia Karkampouna, Panagiota Papadopoulou, Bochuan Hu, Shuya Zang, Emma Wezenberg, Gabriel Forn-Cuní, Bruno Lopes-Bastos and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. NEAT1 Promotes Epileptogenesis in Tuberous Sclerosis Complex.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gangyin ZhaoDepartment of Cellular Tumor Biology, Leiden Institute of Biology, Leiden University, Einsteinweg 55, Leiden 2333 CC, the Netherlands.
Ye ZengDepartment of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, the Netherlands.
Wanli ChengUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern 3010, Switzerland.
Sofia KarkampounaUrology Research Laboratory, Department for BioMedical Research, University of Bern, Bern 3010, Switzerland.
Panagiota PapadopoulouDepartment of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, the Netherlands.
Bochuan HuDepartment of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, the Netherlands.
Shuya ZangDepartment of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, the Netherlands.
Emma WezenbergDepartment of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, the Netherlands.
Gabriel Forn-CuníDepartment of Cellular Tumor Biology, Leiden Institute of Biology, Leiden University, Einsteinweg 55, Leiden 2333 CC, the Netherlands.ORCID 0000-0001-5976-4759
Bruno Lopes-BastosDepartment of Cellular Tumor Biology, Leiden Institute of Biology, Leiden University, Einsteinweg 55, Leiden 2333 CC, the Netherlands.
Marianna Kruithof-de JulioDepartment of Urology, Inselspital, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
Alexander KrosDepartment of Supramolecular & Biomaterials Chemistry, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, Leiden 2333 CC, the Netherlands.ORCID 0000-0002-3983-3048
B Ewa Snaar-JagalskaDepartment of Cellular Tumor Biology, Leiden Institute of Biology, Leiden University, Einsteinweg 55, Leiden 2333 CC, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA therapeutics offer a promising approach to cancer treatment by precisely regulating cancer-related genes. While lipid nanoparticles (LNPs) are currently the most advanced nonviral clinically approved vectors for RNA therapeutics, their antitumor efficacy is limited by their unspecific hepatic accumulation after systemic administration. Thus, there is an urgent need to enhance the delivery efficiency of LNPs to target tumor-residing tissues. Here, we conjugated the cluster of differentiation 44 (CD44)-specific targeting peptide A6 (KPSSPPEE) to the cholesterol of LNPs via PEG, named AKPC-LNP, enabling specific tumor delivery. This modification significantly improved delivery to breast cancer cells both

Indexed as

Antineoplastic AgentsBreast NeoplasmsLipidsNanoparticlesPeptidesRNA, Small InterferingAnimalsCell Line, TumorCell ProliferationFemaleHumansLiposomesMaleMiceXenograft Model Antitumor AssaysZebrafishAntineoplastic AgentsLipid NanoparticlesLipidsLiposomesPeptidesRNA, Small InterferingCD44lipid nanoparticlespatient-derived PDXtumor targetingYAP/TAZ siRNAzebrafish

Identifiers

PMID40176316
PMCPMC12004924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.